10x Genomics, Inc. TXG recently secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen QGEN subsidiary. The Delaware jury found Parse infringed three patents licensed to Scale Biosciences, upheld the patents' validity and awarded damages to TXG.
From an investor's perspective, the ruling reinforces 10x Genomics' intellectual property position in the single-cell analysis market and could support additional financial recovery through post-trial proceedings. Investors will likely watch whether the company secures enhanced damages or further protections for its technology in the U.S. market.
Likely Trend of TXG Stock Following the News
However, following the announcement, shares of TXG slipped more than 5% on Friday. Year to date, shares of the company have surged 277.4% compared with the industry’s 11.4% growth. However, the S&P 500 has risen 12.3% in the same timeframe.
In the long run, the verdict could strengthen 10x Genomics' competitive position by reinforcing the value of its single-cell sequencing intellectual property portfolio, a key differentiator in the genomics market. If the company secures enhanced damages or a permanent injunction in post-trial proceedings, it could discourage future infringement, protect market share and support continued investment in innovation across its expanding single-cell and spatial biology businesses.
TXG currently has a market capitalization of $8.02 billion.
Image Source: Zacks Investment Research
Details of the News
The U.S. District Court for the District of Delaware found that Parse Biosciences, now a Qiagen subsidiary, willfully infringed three patents exclusively licensed to Scale Biosciences, which became part of 10x Genomics in 2025. The patents, originally licensed from Roche Sequencing Solutions, cover foundational single-cell analysis technologies. Importantly, the jury rejected Parse's invalidity arguments and upheld the validity and enforceability of all three patents, strengthening 10x Genomics' intellectual property portfolio in the fast-growing genomics space.
The lawsuit centered on Parse's Evercode Whole Transcriptome products, with the jury concluding that infringing sales occurred from February 2021 through June 30, 2026. Based on a 14% royalty rate on those sales, the jury awarded more than $4.8 million in damages to 10x Genomics. The ruling follows a patent dispute that had been unfolding in Delaware federal court since 2022, making it one of the notable intellectual property battles in the single-cell sequencing market.
What's Next for Qiagen's Parse Business?
The legal process is not over yet. In post-trial proceedings, 10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent injunction that would prevent Parse from continuing to sell the infringing products in the United States. For Qiagen, the next phase of the case could determine whether Parse must modify its U.S. product strategy, secure licensing arrangements or pursue additional legal options as the court considers the requested remedies.
Industry Prospects Favoring the Market
Per a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.
Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.
10x Genomics Price
10x Genomics price | 10x Genomics Quote
Other News
Recently, 10x Genomics exited the second quarter of 2026 with better-than-expected results, as both earnings and revenues beat the Zacks Consensus Estimate. Reported revenues declined year over year due to lower non-recurring license and royalty revenues. However, the underlying business remained resilient. Products and Services revenues increased, supported by growth in Single Cell and Spatial consumables and higher services revenues. Gross margin expansion was another positive, although the company swung to an operating loss from year-ago operating income.
Atera remained the key development in the quarter. Customer response was strong, with booked orders at the end of the second quarter already well above the roughly 40 instruments previously expected for 2026. TXG continues to expect shipments of around 40 units this year as manufacturing capacity ramps. The company expects Atera-related transition dynamics to weigh on third-quarter revenues as customers moderate purchases of existing Spatial products.
TXG’s Zacks Rank & Key Picks
Currently, TXG has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Globus Medical GMED and West Pharmaceutical WST.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN): Free Stock Analysis Report
10x Genomics (TXG): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).